RxDoctor Payments Data

Okechukwu Ibeanu, MD

Urogynecology and Reconstructive Pelvic Surgery · Clinton, MDNPI 1538182571

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.3% of the total across 74 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 22.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $708 and has fallen 50.8% since, to $349 in 2025.

$1,838in general payments, 2019–2025

Across 74 payments — averaging $24.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$419
  • Astellas Pharma US Inc$184
  • Baxter Healthcare$177
  • Johnson & Johnson$137
  • Caldera Medical, Inc$103
  • Boston Scientific$82
  • plus $737 from 21 others

What the payments were for

  • Food & beverage$1,67891%
  • Education$1619%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few urogynecology and reconstructive pelvic surgery providers in Marylandto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$85,647
Medicare patients
170
Services billed
346

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Solifenacin Succinate45$3,138
Oxybutynin Chloride ErOxybutynin Chloride19$545
Medroxyprogesterone Acetate21$397
Megestrol Acetate15$344
Tramadol Hcl17$56
Ciprofloxacin Hcl12$53

Paid to pharmacies, not to this prescriber.

Other urogynecology and reconstructive pelvic surgery in Clinton

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →